夫西地酸钠联合磷霉素钠治疗MRS感染的临床疗效观察

摘要

目的 评价夫西地酸钠联合磷霉素钠治疗耐甲氧西林葡萄球菌(MRS)院内感染的疗效性和安全性.方法 回顾性分析我院3年来临床夫西地酸钠联合磷霉素钠治疗耐甲氧西林葡萄球菌院内感染的265例患者的临床资料.数据资料采用SPSS13.0分析软件进行统计分析,计量资料采用t检验,组间比较采用x2检验,以P＜0.05为差异有统计学意义.结果 2009年1月至2011年12月265例耐甲氧西林葡萄球菌院内感染患者中,耐甲氧西林金黄色葡萄球菌(MRSA)和耐甲氧西林表皮葡萄球菌(MRSE)分别为139例(52.5％)和126例(47.5％).夫西地酸钠联合磷霉素钠治疗的有效率为90.2％,细菌清除率为81.5％,药物的主要不良反应为静脉炎,发生率为7.5％.结论 夫西地酸钠联合磷霉素钠治疗耐甲氧西林葡萄球菌感染安全、有效,临床可根据患者感染的具体状况选择夫西地酸钠联合磷霉素钠优化治疗.%Objective To evaluate the efficacy and security of combining sodium fusidate and sodium fosfomycin in the treatment of hospital acquired methicillin-resistant staphylococci (MRS) infection.Methods 265 hospital acquired MRS infection patients who treated with combining sodium fusidate and sodium fosfomycin were analyzed.All the data information were processed by using SPSS 13.0,measurement data were analyzed by t testing,comparison between groups were analyzed by x2 test,the difference is statistically significant when P ＜0.05.Results From January 2009 to December 2011,there were 139 (52.5％) methicillin-resistant Staphylococcus aureus (MRSA)and 126 (47.5％) methicillin resistant Staphylococcus epidermidis (MRSE) in 265 hospital acquired MRS infection patients whom treated with combining sodium fusidate and sodium fosfomycin.Clinical effective incidence was 90.2％ and bacterial eradication incidence was 81.5％.The principal adverse drug reaction was phlebitis,it's incidence was 7.5％.Conclusion Combining sodium fusidate and sodium fosfomycin for treating hospital acquired MRS infection patients was safe and effective,clinical doctors should choose this optimization treatment for treating MRS infection according to condition of patients.